Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 871 Präparate · 48256 Quellenpassagen · 124 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 15
HOS-086241 · Präparat HOS-083284
Divalproex, lamotrigine, phenytoin Ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent induces
oxidation by CYP2C9 and glucuronidation and as a result is expected to decrease
the plasma concentrations of anticonvulsants. Careful monitoring of serum levels or
therapeutic effects is recommended when these medicines are concomitantly
administered with ritonavir. Phenytoin may decrease serum levels of ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 0462556bf0feaf8f7ced7686eec5b25e4850f1614011df78908f6880001bcb2a · Zeichen 24433–25018 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 48
HOS-086436 · Präparat HOS-083284
Divalproex, lamotrigine, phenytoin Ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent induces
oxidation by CYP2C9 and glucuronidation and as a result is expected to decrease the
plasma concentrations of anticonvulsants. Careful monitoring of serum levels or
therapeutic effects is recommended when these medicines are concomitantly administered
with ritonavir. Phenytoin may decrease serum levels of ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage a2b968972741c754ba4ae051bd3c5e748660eadce5549171f7c2de81e73e900e · Zeichen 26117–26722 im Abschnitt
Wechselwirkungen · Xenical
Xenical 120 mg hard capsules · Abschnitt 4.5 · PDF-Seite 4
HOS-087477 · Präparat HOS-083511
Convulsions have been reported in patients treated concomitantly with orlistat and antiepileptic drugs
e.g. valproate, lamotrigine, for which a causal relationship to an interaction cannot be excluded.
Therefore, these patients should be monitored for possible changes in the frequency and/or severity of
convulsions.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): valproate (HOS-085955) lamotrigine (HOS-086242)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-05-10T13:00:00Z · SHA-256 632b9f6a72b3014c31eea28c23202ae6368254ac0e6429088389d3ea57a05739 · Passage 680af1c39831df0c28d9201f4ef77feed8e745748ad43da7b3abe4ff44d0175b · Zeichen 2073–2390 im Abschnitt
Wechselwirkungen · Keppra
Keppra 250 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-090744 · Präparat HOS-084117
Antiepileptic medicinal products
Pre-marketing data from clinical studies conducted in adults indicate that levetiracetam did not
influence the serum concentrations of existing antiepileptic medicinal products (phenytoin,
carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin and primidone) and that these
antiepileptic medicinal products did not influence the pharmacokinetics of levetiracetam.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): gabapentin (HOS-090745) primidone (HOS-090551) phenytoin (HOS-084531) carbamazepine (HOS-085618) valproic acid (HOS-088515) phenobarbital (HOS-085617) lamotrigine (HOS-086242)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-01T12:51:00Z · SHA-256 0c9c2dbe2cf9e6cd5c8f5c1f489027f4a1e9204a5531ad8b866e3bc0e64b2e72 · Passage 0775e6171215eb0569da08928f886942e0f92db9d8c5e7905bae00c9afcc1d5d · Zeichen 0–410 im Abschnitt
Wechselwirkungen · Keppra
Keppra 500 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 23
HOS-090773 · Präparat HOS-084117
Antiepileptic medicinal products
Pre-marketing data from clinical studies conducted in adults indicate that levetiracetam did not
influence the serum concentrations of existing antiepileptic medicinal products (phenytoin,
carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin and primidone) and that these
antiepileptic medicinal products did not influence the pharmacokinetics of levetiracetam.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenytoin (HOS-084531) carbamazepine (HOS-085618) valproic acid (HOS-088515) phenobarbital (HOS-085617) lamotrigine (HOS-086242) gabapentin (HOS-090745) primidone (HOS-090551)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-01T12:51:00Z · SHA-256 0c9c2dbe2cf9e6cd5c8f5c1f489027f4a1e9204a5531ad8b866e3bc0e64b2e72 · Passage 0775e6171215eb0569da08928f886942e0f92db9d8c5e7905bae00c9afcc1d5d · Zeichen 0–410 im Abschnitt
Wechselwirkungen · Keppra
Keppra 750 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 40
HOS-090798 · Präparat HOS-084117
Antiepileptic medicinal products
Pre-marketing data from clinical studies conducted in adults indicate that levetiracetam did not
influence the serum concentrations of existing antiepileptic medicinal products (phenytoin,
carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin and primidone) and that these
antiepileptic medicinal products did not influence the pharmacokinetics of levetiracetam.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenytoin (HOS-084531) carbamazepine (HOS-085618) valproic acid (HOS-088515) phenobarbital (HOS-085617) lamotrigine (HOS-086242) gabapentin (HOS-090745) primidone (HOS-090551)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-01T12:51:00Z · SHA-256 0c9c2dbe2cf9e6cd5c8f5c1f489027f4a1e9204a5531ad8b866e3bc0e64b2e72 · Passage 0775e6171215eb0569da08928f886942e0f92db9d8c5e7905bae00c9afcc1d5d · Zeichen 0–410 im Abschnitt
Wechselwirkungen · Keppra
Keppra 1000 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 57
HOS-090823 · Präparat HOS-084117
Antiepileptic medicinal products
Pre-marketing data from clinical studies conducted in adults indicate that levetiracetam did not
influence the serum concentrations of existing antiepileptic medicinal products (phenytoin,
carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin and primidone) and that these
antiepileptic medicinal products did not influence the pharmacokinetics of levetiracetam.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenytoin (HOS-084531) carbamazepine (HOS-085618) valproic acid (HOS-088515) phenobarbital (HOS-085617) lamotrigine (HOS-086242) gabapentin (HOS-090745) primidone (HOS-090551)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-01T12:51:00Z · SHA-256 0c9c2dbe2cf9e6cd5c8f5c1f489027f4a1e9204a5531ad8b866e3bc0e64b2e72 · Passage 0775e6171215eb0569da08928f886942e0f92db9d8c5e7905bae00c9afcc1d5d · Zeichen 0–410 im Abschnitt
Wechselwirkungen · Keppra
Keppra 100 mg/ml oral solution · Abschnitt 4.5 · PDF-Seite 75
HOS-090848 · Präparat HOS-084117
Antiepileptic medicinal products
Pre-marketing data from clinical studies conducted in adults indicate that levetiracetam did not
influence the serum concentrations of existing antiepileptic medicinal products (phenytoin,
carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin and primidone) and that these
antiepileptic medicinal products did not influence the pharmacokinetics of levetiracetam.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenytoin (HOS-084531) carbamazepine (HOS-085618) valproic acid (HOS-088515) phenobarbital (HOS-085617) lamotrigine (HOS-086242) gabapentin (HOS-090745) primidone (HOS-090551)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-01T12:51:00Z · SHA-256 0c9c2dbe2cf9e6cd5c8f5c1f489027f4a1e9204a5531ad8b866e3bc0e64b2e72 · Passage 0775e6171215eb0569da08928f886942e0f92db9d8c5e7905bae00c9afcc1d5d · Zeichen 0–410 im Abschnitt
Wechselwirkungen · Keppra
Keppra 100 mg/ml concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 91
HOS-090874 · Präparat HOS-084117
Antiepileptic medicinal products
Pre-marketing data from clinical studies conducted in adults indicate that levetiracetam did not
influence the serum concentrations of existing antiepileptic medicinal products (phenytoin,
carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin and primidone) and that these
antiepileptic medicinal products did not influence the pharmacokinetics of levetiracetam.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenytoin (HOS-084531) carbamazepine (HOS-085618) valproic acid (HOS-088515) phenobarbital (HOS-085617) lamotrigine (HOS-086242) gabapentin (HOS-090745) primidone (HOS-090551)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-01T12:51:00Z · SHA-256 0c9c2dbe2cf9e6cd5c8f5c1f489027f4a1e9204a5531ad8b866e3bc0e64b2e72 · Passage 0775e6171215eb0569da08928f886942e0f92db9d8c5e7905bae00c9afcc1d5d · Zeichen 0–410 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 16–17
HOS-108891 · Präparat HOS-093083
16
Lamotrigine and Valproate Lamotrigine: Patients should be monitored
AUC: ↓ 50% closely for a decreased VPA effect
Cmax: ↓ 46% when Kaletra and valproic acid or
Cmin: ↓ 56% valproate are given concomitantly.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): valproic acid (HOS-088515) lamotrigine (HOS-086242) valproate (HOS-085955)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage a7e82911dccca80dc82fcd7b0c00f0f1a374aaafbd9655160ced2206706c3122 · Zeichen 26655–27055 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 17
HOS-108895 · Präparat HOS-093083
Due to induction of lamotrigine In patients starting or stopping
glucuronidation Kaletra while currently taking
maintenance dose of lamotrigine:
Valproate: ↓ lamotrigine dose may need to be
increased if Kaletra is added, or
decreased if Kaletra is
discontinued; therefore plasma
lamotrigine monitoring should be
conducted, particularly before and
during 2 weeks after starting or
stopping Kaletra, in order to see if
lamotrigine dose adjustment is
needed.
In patients currently taking Kaletra
and starting lamotrigine: no dose
adjustments to the recommended
dose escalation of lamotrigine
should be necessary.
Antidepressants and Anxiolytics
Trazodone single dose Trazodone: It is unknown whether the
AUC: ↑ 2.4-fold combination of Kaletra causes a
(Ritonavir, 200 mg BID) similar increase in trazodone
Adverse events of nausea, exposure. The combination should
dizziness, hypotension and be used with caution and a lower
syncope were observed following dose of trazodone should be
co-administration of trazodone considered.
and ritonavir.
Antifungals
Ketoconazole and Ketoconazole, Itraconazole: High doses of ketoconazole and
Itraconazole Serum concentrations may be itraconazole (> 200 mg/day) are
increased due to CYP3A not recommended.
inhibition by lopinavir/ritonavir.
Voriconazole Voriconazole: Co-administration of voriconazole
Concentrations may be decreased. and low dose ritonavir (100 mg
BID) as contained in Kaletra
should be avoided unless an
assessment of the benefit/risk to
patient justifies the use of
voriconazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) valproate (HOS-085955) trazodone (HOS-086251) ketoconazole (HOS-084513) itraconazole (HOS-084516) voriconazole (HOS-084524)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage cc67e2cdf7b4bd67992a77fee82c028a01ca61b900711d375f1043368d2697bb · Zeichen 27086–30540 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 52–53
HOS-109011 · Präparat HOS-093083
52
Kaletra must not be administered
once daily in combination with
phenytoin.
Carbamazepine and Carbamazepine: Caution should be exercised in
Phenobarbital Serum concentrations may be administering carbamazepine or
increased due to CYP3A phenobarbital with Kaletra.
inhibition by lopinavir/ritonavir. Carbamazepine and phenobarbital
levels should be monitored when
Lopinavir: co-administering with Kaletra.
Concentrations may be decreased When co-administered with
due to CYP3A induction by carbamazepine or phenobarbital, an
carbamazepine and phenobarbital. increase of Kaletra dosage may be
envisaged. Dose adjustment has not
been evaluated in clinical practice.
Kaletra must not be administered
once daily in combination with
carbamazepine and phenobarbital.
Lamotrigine and Lamotrigine: Patients should be monitored closely
Valproate AUC: ↓ 50% for a decreased VPA effect when
Cmax: ↓ 46% Kaletra and valproic acid or valproate
Cmin: ↓ 56% are given concomitantly.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenytoin (HOS-084531) carbamazepine (HOS-085618) phenobarbital (HOS-085617) lamotrigine (HOS-086242) valproate (HOS-085955) valproic acid (HOS-088515)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 7ab99d1352f73d28a2d94a0c91058c6dc39f0bd1e0fb1d81b22f720114b89a89 · Zeichen 24661–26644 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 53
HOS-109012 · Präparat HOS-093083
Due to induction of lamotrigine In patients starting or stopping
glucuronidation Kaletra while currently taking
maintenance dose of lamotrigine:
Valproate: ↓ lamotrigine dose may need to be
increased if Kaletra is added, or
decreased if Kaletra is discontinued;
therefore plasma lamotrigine
monitoring should be conducted,
particularly before and during 2
weeks after starting or stopping
Kaletra, in order to see if lamotrigine
dose adjustment is needed.
In patients currently taking Kaletra
and starting lamotrigine: no dose
adjustments to the recommended
dose escalation of lamotrigine should
be necessary.
Antidepressants and Anxiolytics
Trazodone single dose Trazodone: It is unknown whether the
AUC: ↑ 2.4-fold combination of Kaletra causes a
(Ritonavir, 200 mg similar increase in trazodone
BID) Adverse events of nausea, exposure. The combination should
dizziness, hypotension and be used with caution and a lower dose
syncope were observed following of trazodone should be considered.
co-administration of trazodone
and ritonavir.
Antifungals
Ketoconazole and Ketoconazole, Itraconazole: High doses of ketoconazole and
Itraconazole Serum concentrations may be itraconazole (> 200 mg/day) are not
increased due to CYP3A recommended.
inhibition by lopinavir/ritonavir.
Voriconazole Voriconazole: Co-administration of voriconazole
Concentrations may be decreased. and low dose ritonavir (100 mg BID)
as contained in Kaletra should be
avoided unless an assessment of the
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) valproate (HOS-085955) trazodone (HOS-086251) ketoconazole (HOS-084513) itraconazole (HOS-084516) voriconazole (HOS-084524)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage b7549f913c063162484a547a54d17aa41fc44fb9504b9f1472817c41a1f18572 · Zeichen 26672–29701 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 87–88
HOS-109085 · Präparat HOS-093083
87
Rivaroxaban Rivaroxaban: Co-administration of rivaroxaban
AUC: ↑ 153% and Kaletra may increase
(Ritonavir 600 mg twice Cmax: ↑ 55% rivaroxaban exposure which may
daily) Due to CYP3A and P-gp increase the risk of bleeding.
inhibition by lopinavir/ritonavir. The use of rivaroxaban is not
recommended in patients receiving
concomitant treatment with Kaletra
(see section 4.4).
Dabigatran etexilate, Dabigatran etexilate, Clinical monitoring and/or dose
Edoxaban Edoxaban: reduction of the direct oral
Serum concentrations may be anticoagulants (DOAC) should be
increased due to Pgp inhibition by considered when a DOAC
lopinavir/ritonavir. transported by P-gp but not
metabolised by CYP3A4, including
dabigatran etexilate and edoxaban,
is co-administered with Kaletra.
Anticonvulsants
Phenytoin Phenytoin: Caution should be exercised in
Steady-state concentrations was administering phenytoin with
moderately decreased due to Kaletra.
CYP2C9 and CYP2C19 induction Phenytoin levels should be
by lopinavir/ritonavir. monitored when co-administering
with Kaletra.
Lopinavir: When co-administered with
Concentrations are decreased due phenytoin, an increase of Kaletra
to CYP3A induction by dosage may be envisaged. Dose
phenytoin. adjustment has not been evaluated
in clinical practice.
Kaletra must not be administered
once daily in combination with
phenytoin.
Carbamazepine and Carbamazepine: Caution should be exercised in
Phenobarbital Serum concentrations may be administering carbamazepine or
increased due to CYP3A phenobarbital with Kaletra.
inhibition by lopinavir/ritonavir. Carbamazepine and phenobarbital
levels should be monitored when
Lopinavir: co-administering with Kaletra.
Concentrations may be decreased When co-administered with
due to CYP3A induction by carbamazepine or phenobarbital, an
carbamazepine and phenobarbital. increase of Kaletra dosage may be
envisaged. Dose adjustment has not
been evaluated in clinical practice.
Kaletra must not be administered
once daily in combination with
carbamazepine and phenobarbital.
Lamotrigine and Lamotrigine: Patients should be monitored
Valproate AUC: ↓ 50% closely for a decreased VPA effect
Cmax: ↓ 46% when Kaletra and valproic acid or
Cmin: ↓ 56% valproate are given concomitantly.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rivaroxaban (HOS-086236) dabigatran etexilate (HOS-086233) edoxaban (HOS-086234) phenytoin (HOS-084531) carbamazepine (HOS-085618) phenobarbital (HOS-085617) lamotrigine (HOS-086242) valproate (HOS-085955) valproic acid (HOS-088515)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 0668c273c88d1ae41827a69ac1504dff6543bd6b0d2a053e402140143e6219fb · Zeichen 22156–26627 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 88
HOS-109086 · Präparat HOS-093083
Due to induction of lamotrigine In patients starting or stopping
glucuronidation Kaletra while currently taking
maintenance dose of lamotrigine:
Valproate: ↓ lamotrigine dose may need to be
increased if Kaletra is added, or
decreased if Kaletra is discontinued;
therefore plasma lamotrigine
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) valproate (HOS-085955)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 128daa62a80bd4f26f7f314d41c5bda0db9b03af516d8ea5e69c5737be7f924b · Zeichen 26655–27299 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 88–89
HOS-109087 · Präparat HOS-093083
88
monitoring should be conducted,
particularly before and during 2
weeks after starting or stopping
Kaletra, in order to see if
lamotrigine dose adjustment is
needed.
In patients currently taking Kaletra
and starting lamotrigine: no dose
adjustments to the recommended
dose escalation of lamotrigine
should be necessary.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 98c3ddec32a2ab6887b7be35b15fd76839d885e574042c028f8dd757e7bef2d3 · Zeichen 27344–28359 im Abschnitt
Wechselwirkungen · Evra
EVRA 203 micrograms/24 hours + 33.9 micrograms/24 hours transdermal patch · Abschnitt 4.5 · PDF-Seite 12
HOS-110320 · Präparat HOS-093363
Lamotrigine: Combined hormonal contraceptives have been shown to significantly decrease plasma
concentrations of lamotrigine when coadministered likely due to induction of lamotrigine
glucuronidation. This may reduce seizure control; therefore, dosage adjustments of lamotrigine may be
necessary.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-22T17:22:00Z · SHA-256 08ee5b4a9562d12725bc2847cb5a881102ab4ddbaaf7c1a2e28b65b78fd2ab5d · Passage 2284f2100c066952c3c8cc53a59d2e401048aea9436025c695f8985cc9f5fbb8 · Zeichen 4149–4445 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 18
HOS-112100 · Präparat HOS-093615
Close monitoring of patient's
virologic response should be
exercised.
Lamotrigine Co-administration of lamotrigine and Lamotrigine should be used with
REYATAZ/ritonavir may decrease caution in combination with
lamotrigine plasma concentrations due to REYATAZ/ritonavir.
UGT1A4 induction.
If necessary, monitor lamotrigine
concentrations and adjust the dose
accordingly.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage c0d169537f6b9d44b62dd3cd4db3f2f2d17bcfc9ac0461bd605913f3763c260d · Zeichen 44433–45292 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 24–25
HOS-112119 · Präparat HOS-093615
24
In case of withdrawal of ritonavir from the recommended atazanavir-boosted regimen
(see section 4.4)
The same recommendations for drug interactions would apply except:
that co-administration is not recommended with tenofovir, proton pump inhibitors, and
buprenorphine and contraindicated with carbamazepine, phenytoin and phenobarbital.
that co-administration with famotidine is not recommended but if required, atazanavir without
ritonavir should be administered either 2 hours after famotidine or 12 hours before. No single
dose of famotidine should exceed 20 mg, and the total daily dose of famotidine should not
exceed 40 mg.
the need to consider that:
co-administration of apixaban, dabigatran, or rivaroxaban and REYATAZ without
ritonavir may affect apixaban, dabigatran, or rivaroxaban concentrations
co-administration of voriconazole and REYATAZ without ritonavir may affect atazanavir
concentrations
co-administration of fluticasone and REYATAZ without ritonavir may increase
fluticasone concentrations relative to fluticasone given alone
if an oral contraceptive is administered with REYATAZ without ritonavir, it is
recommended that the oral contraceptive contain no more than 30 μg of ethinyloestradiol
no dose adjustment of lamotrigine is required
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): apixaban (HOS-112091) dabigatran (HOS-112096) rivaroxaban (HOS-086236) voriconazole (HOS-084524) fluticasone (HOS-108914) lamotrigine (HOS-086242) ritonavir (HOS-084521) tenofovir (HOS-088083) buprenorphine (HOS-086193) carbamazepine (HOS-085618) phenytoin (HOS-084531) phenobarbital (HOS-085617) famotidine (HOS-112087)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage e782985711b73a21e78ab499d92e8fece89fe8ca127ddbacf1a99dce682dcc07 · Zeichen 75495–76934 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 54
HOS-112191 · Präparat HOS-093615
Close monitoring of patient's
virologic response should be
exercised.
Lamotrigine Co-administration of lamotrigine and Lamotrigine should be used
REYATAZ/ritonavir may decrease with caution in combination
lamotrigine plasma concentrations due to with REYATAZ/ritonavir.
UGT1A4 induction.
If necessary, monitor
lamotrigine concentrations and
adjust the dose accordingly.
ANTINEOPLASTICS AND IMMUNOSUPRESSANTS
Antineoplastics
Apalutamide The mechanism of interaction is CYP3A4 Co-administration with
induction by apalutamide and CYP3A4 REYATAZ (with or without
inhibition by atazanavir/ritonavir. ritonavir) is contraindicated
due to the potential for
decreased atazanavir and
ritonavir plasma concentration
with subsequent loss of
virologic response and possible
resistance to the class of
protease inhibitors (see
section 4.3). In addition, serum
concentrations of apalutamide
may be increased when
coadministered with
atazanavir/ritonavir, resulting
in the potential for serious
adverse events including
seizure.
Encorafenib The mechanism of interaction is CYP3A4 Co-administration of
inhibition by atazanavir and/or ritonavir. encorafenib with REYATAZ
(with or without ritonavir) is
contraindicated due to potential
for loss of virologic response,
development of resistance,
increase in encorafenib plasma
concentration and subsequent
risk of serious adverse events
such as QT interval
prolongation (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) ritonavir (HOS-084521) apalutamide (HOS-086212) protease (HOS-085623) encorafenib (HOS-086222)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 76cd05b5753aea8ee1aca9c616b6de829a0e30efc35a847539ed861c81939295 · Zeichen 45824–49596 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.